

A.O. Ordine Mauriziano di Torino

Titolo:	IMPACT-AML: A Randomized Pragmatic Clinical Trial For Relapse Or Refractory Acute Myeloid Leukemia
Codice studio	IRST204.07
Patologia:	Leucemia mieloide acuta
Tipo di Studio:	Interventistico
Tipologia	no profit
Fase:	3
Principali criteri di inclusione:	• Non-APL AML defined according WHO 2022 (or ICC 2022) criteria • 1st or 2nd relapse or refractory according to ELN 2022 • Patient is clinically candidate either to low intensity therapy or to high dose chemotherapy in the opinion of the physician
Principali criteri di esclusione:	• Participation in another clinical trial with any investigational agents within 14 days or 5 drug half-lives (whatever comes first) prior to randomization • Active infections or other clinical conditions that in the opinion of the investigator make the patient ineligible to receive study treatment
Struttura	SCDU Ematologia e Terapie Cellulari
Contatto	Prof.ssa Daniela Cilloni daniela.cilloni@unito.it